OBJECTIVES: Experimental studies have shown involvement of Wnt signalling in heart failure (HF). We hypothesized that secreted frizzled-related protein 3 (sFRP3), a modulator of Wnt signalling, is related to the progression of HF. DESIGN: Circulating sFRP3 was measured in 153 HF patients and compared with 25 healthy controls. The association of sFRP3 with mortality was evaluated in 1202 patients (GISSI-HF trial). sFRP3 mRNA expression was assessed in failing human and murine left ventricles (LV), and cellular localization was determined after fractioning of myocardial tissue. In vitro studies were carried out in cardiac fibroblasts subjected to cyclic mechanical stretch. RESULTS: (i) Heart failure patients had significantly raised serum sFRP3 levels compared with controls, (ii) during a median follow-up of 47 months, 315 patients died in the GISSI-HF substudy. In univariable Cox regression, tertiles of baseline sFRP3 concentration were significantly associated with all-cause and cardiovascular mortality. After adjustment for demographic and clinical variables, but not for CRP and NT-proBNP, the associations with mortality remained significant for the third tertile (all-cause, HR 1.45, P = 0.011; cardiovascular, HR 1.66, P = 0.003), (iii) sFRP3 mRNA expression was increased in failing human LV, with a decline following LV assist device therapy. LV from post-MI mice showed an increased sFRP3 mRNA level, particularly in cardiac fibroblasts, and (iv) mechanical stretch enhanced sFRP3 expression and release in myocardial fibroblasts. CONCLUSION: There is an association between increased sFRP3 expression and adverse outcome in HF, suggesting that the failing myocardium itself contributes to an increase in circulating sFRP3.
OBJECTIVES: Experimental studies have shown involvement of Wnt signalling in heart failure (HF). We hypothesized that secreted frizzled-related protein 3 (sFRP3), a modulator of Wnt signalling, is related to the progression of HF. DESIGN: Circulating sFRP3 was measured in 153 HF patients and compared with 25 healthy controls. The association of sFRP3 with mortality was evaluated in 1202 patients (GISSI-HF trial). sFRP3 mRNA expression was assessed in failing human and murine left ventricles (LV), and cellular localization was determined after fractioning of myocardial tissue. In vitro studies were carried out in cardiac fibroblasts subjected to cyclic mechanical stretch. RESULTS: (i) Heart failurepatients had significantly raised serum sFRP3 levels compared with controls, (ii) during a median follow-up of 47 months, 315 patients died in the GISSI-HF substudy. In univariable Cox regression, tertiles of baseline sFRP3 concentration were significantly associated with all-cause and cardiovascular mortality. After adjustment for demographic and clinical variables, but not for CRP and NT-proBNP, the associations with mortality remained significant for the third tertile (all-cause, HR 1.45, P = 0.011; cardiovascular, HR 1.66, P = 0.003), (iii) sFRP3 mRNA expression was increased in failing human LV, with a decline following LV assist device therapy. LV from post-MI mice showed an increased sFRP3 mRNA level, particularly in cardiac fibroblasts, and (iv) mechanical stretch enhanced sFRP3 expression and release in myocardial fibroblasts. CONCLUSION: There is an association between increased sFRP3 expression and adverse outcome in HF, suggesting that the failing myocardium itself contributes to an increase in circulating sFRP3.
Authors: Han Zhou; Sameet Mehta; Swayam Prakash Srivastava; Kariona Grabinska; Xinbo Zhang; Chris Wong; Ahmad Hedayat; Paola Perrotta; Carlos Fernández-Hernando; William C Sessa; Julie E Goodwin Journal: JCI Insight Date: 2020-02-13
Authors: Aurelija Abraityte; Leif E Vinge; Erik T Askevold; Tove Lekva; Annika E Michelsen; Trine Ranheim; Katrine Alfsnes; Arnt Fiane; Svend Aakhus; Ida G Lunde; Christen P Dahl; Pål Aukrust; Geir Christensen; Lars Gullestad; Arne Yndestad; Thor Ueland Journal: J Mol Med (Berl) Date: 2017-03-30 Impact factor: 4.599
Authors: Sébastien Foulquier; Evangelos P Daskalopoulos; Gentian Lluri; Kevin C M Hermans; Arjun Deb; W Matthijs Blankesteijn Journal: Pharmacol Rev Date: 2018-01 Impact factor: 25.468
Authors: Dorothy E Vatner; Jie Zhang; Xin Zhao; Lin Yan; Raymond Kudej; Stephen F Vatner Journal: Am J Physiol Heart Circ Physiol Date: 2020-12-18 Impact factor: 4.733
Authors: Meaghan Lunney; Marinella Ruospo; Patrizia Natale; Robert R Quinn; Paul E Ronksley; Ioannis Konstantinidis; Suetonia C Palmer; Marcello Tonelli; Giovanni Fm Strippoli; Pietro Ravani Journal: Cochrane Database Syst Rev Date: 2020-02-27
Authors: Erik Tandberg Askevold; Lars Gullestad; Ståle Nymo; John Kjekshus; Arne Yndestad; Roberto Latini; John G F Cleland; John J V McMurray; Pål Aukrust; Thor Ueland Journal: PLoS One Date: 2015-08-19 Impact factor: 3.240
Authors: Sabine Charron; François Roubertie; David Benoist; Virginie Dubes; Stephen H Gilbert; Marion Constantin; Delphine Vieillot; Delphine Elbes; Bruno Quesson; Pierre Bordachar; Michel Haissaguerre; Olivier Bernus; Jean-Benoit Thambo; Caroline Rooryck Journal: PLoS One Date: 2015-08-07 Impact factor: 3.240